|
|
7000 Shoreline Court, Suite 270
South San Francisco, CA 94080 USA
phone:650-583-3774
fax:650-583-3789
|
|
| Symbol |
PARD |
| Exchange |
NASDAQ |
| Founded |
1984 |
| Employees |
|
|
|
| www.poniard.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Development, commercialization of oncology products |
|
| Management |
| Jerry McMahon, Ph.D., Chairman and Chief Executive Officer; Ronald A. Martell, President and Chief Operating Officer; Greg Weaver, Chief Financial Officer and Senior Vice President; Robert De Jager, M.D., FACP, Chief Medical Officer; Cheni Kwok, Ph.D., CLP, Senior Vice President, Corporate Development |
| |
|
|
|
|
|
|
|
| Keywords |
| metastatic, colorectal, intravenous picoplat, hormone refractory prostate, cancers |
|
|
|
| Description |
|
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. They are currently focusing development efforts on picoplatin, a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. Picoplatin has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with chemotherapy in solid tumors and delay time to relapse. Poniard is studying picoplatin in multiple cancer indications, combinations and formulations. |
|
| Products / Services |
Poniard Pharmaceuticals is currently conducting clinical trials to evaluate picoplatin in patients with small cell lung cancer, colorectal cancer and hormone-refractory prostate cancer. In addition, preclinical studies are underway to assess the application of picoplatin in an oral formulation.
|
|
| Technology / Differentiation |
| The company's development efforts are focused on picoplatin, a new generation platinum therapy that provides a differentiated spectrum of activity and an improved safety profile. An intravenous chemotherapeutic agent, picoplatin is designed to overcome platinum resistance associated with the treatment of solid tumors. |
|
|
| Strategy |
Poniard is collaborating with the Scripps Florida Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors as therapeutic agents to treat cancer.
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
